KYTX

Kyverna Therapeutics, Inc.

8.28 USD

Last updated Sep 4, 20:05 UTC

Yesterday HIGH

$8.78

Yesterday LOW

$8.28

52w HIGH

$13.67

52w LOW

$3.55

EPS

-0.63

PE

-13.14

Next Earnings

Nov 11, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Kyverna Therapeutics, Inc. stock is up 8.38% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 September’s closed higher than August. In the last 4 Unusual Options Trades, there were 3 CALLs, 1 PUT.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

20 Jul 14:06	21 Aug, 2026	7.50	CALL	910	85
28 Jul 15:54	19 Mar, 2027	7.50	PUT	150	56
31 Aug 19:20	18 Dec, 2026	10.00	CALL	415	764
31 Aug 19:30	18 Dec, 2026	10.00	CALL	250	764

Advanced Data Unlock

Benzinga Newsdesk

Fri May 15, 2026

HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the price target from $20 to $25.
Benzinga Newsdesk

Wed May 13, 2026

JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and lowers the price target from $30 to $29.
Benzinga Newsdesk

Tue May 12, 2026

Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.73) by 9.59 percent. This is a 35.92 percent increase over losses of $(1.03) per share
Benzinga Newsdesk

Thu Apr 23, 2026

HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and maintains $20 price target.
Benzinga Insights

Wed Apr 22, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Avi Kapoor

Wed Apr 22, 2026

Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.
Benzinga Newsdesk

Wed Apr 22, 2026

Reported Earlier, Kyverna's Miv-Cel Meets All Primary And Secondary Endpoints In KYSA-8 Registrational Trial, Potentially First Approved Treatment For Stiff Person Syndrome

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPSData underscore
Mohd Haider

Wed Apr 22, 2026

Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?

Kyverna Therapeutics Inc. shares surged 24% after hours following positive registrational trial results for miv-cel in stiff person syndrome, showing significant improvement in walking speed.
Benzinga Newsdesk

Mon Apr 20, 2026

Kyverna Therapeutics shares are trading higher after the company announced longer-term follow-up data from Phase 2 portion of its registrational KYSA-6 trial of miv-cel in patients with generalized myasthenia gravis.
Benzinga Newsdesk

Thu Apr 2, 2026

Kyverna Therapeutics Enters Open Market Sale Agreement With Jefferies Dated March 27, 2025; Co. May Offer Up To $100M Of Common Stock

-SEC Filing